Cover Image
市場調查報告書

肺部疾病的開發中產品分析

Lung Disease - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 251622
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
肺部疾病的開發中產品分析 Lung Disease - Pipeline Review, H1 2014
出版日期: 2014年03月31日 內容資訊: 英文 55 Pages
簡介

所謂「肺部疾病」(肺病)是肺部各種疾病的總稱。主要的症狀有咳嗽(同時包括有痰及無痰)和倦怠感、各種呼吸系統感染疾病、呼吸急促、肺炎、水腫等。主要的治療藥有吸入式的皮質類固醇劑,及長期作用型的β2受體激動劑,喘克緩釋微粒膠囊等。

本報告提供全球各國治療肺部疾病用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

肺部疾病概要

治療藥的開發

  • 肺部疾病開發中產品:概要
  • 肺部疾病開發中產品:比較分析

各企業開發中的肺部疾病治療藥

大學/研究機關研究中的肺部疾病治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

肺部疾病治療藥:開發中的產品的一覽(各企業)

肺部疾病治療藥:研究中的產品的一覽(大學/研究機關別)

肺部疾病治療藥的開發企業

  • Ablynx NV
  • Vectura Group plc
  • Pharmaxis Limited
  • AGI Therapeutics plc
  • Nostrum Pharmaceuticals, LLC
  • PharmaIN Corporation
  • Paranta Biosciences Limited
  • Serendex Pharmaceuticals A/S

肺部疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 克拉屈濱(cladribine)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • sargramostim
  • VR-461
  • PXS-4206
  • AGI-350
  • dapsone
  • Retinoic Acid Receptor Agonists
  • Recombinant Human Follistatin
  • PGC-VIP
  • Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases
  • Nanobody 1 For Pulmonary Disease
  • Nanobody 2 For Pulmonary Disease
  • Ornithine-Substituted ADP-Ribosyl HNP-1
  • Ornithine-HNP-1

肺部疾病治療藥:暫停開發的產品

肺部疾病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全4件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4744IDB

Global Markets Direct's, 'Lung Disease - Pipeline Review, H1 2014', provides an overview of the Lung Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lung Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lung Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lung Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Disease Overview
  • Therapeutics Development
    • Pipeline Products for Lung Disease - Overview
    • Pipeline Products for Lung Disease - Comparative Analysis
  • Lung Disease - Therapeutics under Development by Companies
  • Lung Disease - Therapeutics under Investigation by Universities/Institutes
  • Lung Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Lung Disease - Products under Development by Companies
  • Lung Disease - Products under Investigation by Universities/Institutes
  • Lung Disease - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Vectura Group plc
    • Pharmaxis Limited
    • AGI Therapeutics plc
    • Nostrum Pharmaceuticals, LLC
    • PharmaIN Corporation
    • Paranta Biosciences Limited
    • Serendex Pharmaceuticals A/S
  • Lung Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cladribine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sargramostim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VR-461 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-4206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGI-350 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dapsone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Retinoic Acid Receptor Agonists - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Human Follistatin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGC-VIP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nanobody 1 For Pulmonary Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nanobody 2 For Pulmonary Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ornithine-Substituted ADP-Ribosyl HNP-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ornithine-HNP-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lung Disease - Dormant Projects
  • Lung Disease - Product Development Milestones
    • Featured News & Press Releases
      • Oct 15, 2013: Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
      • Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants
      • Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease
      • Jan 02, 2012: Commonly Used Blood Pressure Drug Prevents Smoking-related Lung Damage In Mice
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lung Disease, H1 2014
  • Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Lung Disease - Pipeline by Ablynx NV, H1 2014
  • Lung Disease - Pipeline by Vectura Group plc, H1 2014
  • Lung Disease - Pipeline by Pharmaxis Limited, H1 2014
  • Lung Disease - Pipeline by AGI Therapeutics plc, H1 2014
  • Lung Disease - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2014
  • Lung Disease - Pipeline by PharmaIN Corporation, H1 2014
  • Lung Disease - Pipeline by Paranta Biosciences Limited, H1 2014
  • Lung Disease - Pipeline by Serendex Pharmaceuticals A/S, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Lung Disease - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Lung Disease, H1 2014
  • Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top